Update in Diuretic Therapy: Clinical Pharmacology

被引:58
作者
Brater, D. Craig [1 ]
机构
[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA
关键词
Diuretic; edema; renal insufficiency; nephrotic syndrome; cirrhosis; congestive heart failure; CONGESTIVE-HEART-FAILURE; CHRONIC RENAL-INSUFFICIENCY; HIGH-DOSE FUROSEMIDE; TUBULAR SODIUM REABSORPTION; A(1) RECEPTOR ANTAGONIST; DRUG-PROTEIN-BINDING; CONTINUOUS-INFUSION; NEPHROTIC SYNDROME; LOOP DIURETICS; HEPATIC CIRRHOSIS;
D O I
10.1016/j.semnephrol.2011.09.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
All diuretics except spironolactone exert their effects from the lumen of the nephron. Thus, to exert an effect, they must reach the urine. Pharmacokinetics (PK) describes this access. Different edematous disorders can affect access to this site of action and therein affect response to a diuretic. In addition, once a diuretic reaches the site of action, a response ensues. The characteristics of this response that can be affected by a patient's clinical condition are described by the pharmacodynamics (PD) of a diuretic. To understand the mechanisms of abnormal response to a diuretic one must dissect its PK and PD in different edematous disorders. For example, in patients with renal insufficiency, the mechanism of poor diuretic response is PK. In contrast, in patients with cirrhosis or in those with congestive heart failure, it is PD. In patients with nephrotic syndrome, both PK and PD are operative. These different mechanisms mandate differences in therapeutic strategy, as explained in this article. Semin Nephrol 31:483-494 (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:483 / 494
页数:12
相关论文
共 88 条
[1]
Agarwal R, 2000, J AM SOC NEPHROL, V11, P1100, DOI 10.1681/ASN.V1161100
[2]
URINARY SODIUM - POTASSIUM RATIO AND RESPONSE TO DIURETICS IN RESISTANT EDEMA [J].
ALEXANDER, WD ;
BRANCH, RA ;
LEVINE, DF ;
HARTOG, M .
POSTGRADUATE MEDICAL JOURNAL, 1977, 53 (617) :117-121
[3]
ALMESHARI K, 1993, J AM SOC NEPHROL, V3, P1878
[4]
DISTRIBUTION, ELIMINATION AND EFFECT OF FUROSEMIDE IN NORMAL SUBJECTS AND IN PATIENTS WITH HEART-FAILURE [J].
ANDREASEN, F ;
MIKKELSEN, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (01) :15-22
[5]
BIOAVAILABILITY OF BUMETANIDE IN GROSSLY EDEMATOUS PATIENTS [J].
BAILIE, GR ;
GRENNAN, A ;
WALDEK, S .
CLINICAL PHARMACOKINETICS, 1987, 12 (06) :440-443
[6]
BESSEGHIR K, 1981, J PHARMACOL EXP THER, V219, P435
[7]
FUROSEMIDE IN PATIENTS WITH HEART-FAILURE - SHIFT IN DOSE-RESPONSE CURVES [J].
BRATER, DC ;
CHENNAVASIN, P ;
SEIWELL, R ;
BECK, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 28 (02) :182-186
[8]
BRATER DC, 1983, J PHARMACOL EXP THER, V227, P92
[9]
BUMETANIDE AND FUROSEMIDE IN HEART-FAILURE [J].
BRATER, DC ;
DAY, B ;
BURDETTE, A ;
ANDERSON, S .
KIDNEY INTERNATIONAL, 1984, 26 (02) :183-189
[10]
BRATER DC, 1992, VIVO STUDY DRUG ACTI, P253